Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Overview of Anatomy and Physiology
Hypertension II: Pathophysiology
EPS and iPS Cells in Disease Research
Pathophysiology of Heart Failure
Lysosomal Hydrolases
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 4, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Mylène Tajan1, Audrey de Rocca Serra1, Philippe Valet1
1Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Toulouse, France; Université de Toulouse, Université Paul Sabatier, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France.
Mutations in the PTPN11 gene cause developmental disorders like Noonan syndrome and cancers by altering SHP2 phosphatase activity. Understanding these SHP2 dysregulations is key to developing targeted therapies.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: